A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation therapeutic radiopharmaceuticals

Related Keywords

China ,Boston ,Massachusetts ,United States ,Australia ,South Korea ,United Kingdom ,Turkey ,America ,Kostenloser Wertpapierhandel ,Astra Zeneca ,Ian Wilson ,Society Of Immunotherapy Cancer ,Ibm ,Boehringer Ingelheim ,Prnewswire Imaginab Inc ,Melanoma Research Alliance ,Pfizer ,University Of California Davis ,Dongchengpharmaceutical Group ,Memorial Sloan Kettering Cancer Center ,Immunopet Partnership Agreements ,Radiopharmaceutical Therapies ,Biologics License Application ,Inclusion Body Myositis ,Merkel Cell ,Renal Cell ,Non Small Cell Lung Cancer ,California Davis ,Imaging Endpoints ,Territorial Licensing Agreement ,Manufacturing Agreements ,North America ,Pharmaceutical Therapy ,Chief Executive Officer ,Transformational ,Ear ,Imaginab ,Xpands ,Pipeline ,Nclude ,Radiopharmaceutical ,Therapies ,Centers ,Multiple ,Partnerships ,Drives ,Forward ,Development ,Investigational ,Mmunopet ,Agent ,